BC Extra | Feb 1, 2020
Financial News

Arcutis gains in this year’s third biotherapeutic IPO on NASDAQ

The aftermarket performance of two IPOs in January’s final week suggests investors’ appetite for new biotech listings remains robust. In NASDAQ’s third biotherapeutic IPO of the year, dermatology company Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) raised $159.4...
BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BC Extra | Oct 22, 2019
Financial News

Crossover investors help Arcutis raise $95M to advance PDE-4 inhibitor for psoriasis

Arcutis raised $94.5 million in a series C financing to advance lead product ARQ-151, a topical formulation of the PDE-4 inhibitor roflumilast, through Phase III trials for mild-to-moderate psoriasis. Arcutis Biotherapeutics Inc. co-founder Chairman Bhaskar...
BC Extra | Sep 10, 2019
Financial News

Pharvaris raises $66M series B for clinical development of oral HAE therapy

Pharvaris will use its new $66 million series B round to fund early clinical development of its lead compound, an oral small molecule that could give HAE patients an easier-to-use option than existing injectable therapies...
BC Extra | Sep 9, 2019
Company News

Management tracks: Coles to lead Cerevel; plus Genfit, Jubilant, Paratek, Mogrify, Dementia Discovery Fund and Ayala

Cerevel Therapeutics LLC (Boston, Mass.) hired Tony Coles as CEO. Coles is Cerevel’s executive chairman as well as the co-founder and executive chairman of neurodegeneration company Yumanity Therapeutics LLC (Cambridge, Mass.), where he was until...
BC Extra | Aug 15, 2019
Company News

Management tracks: New executives at Pfizer spinouts Cerevel and SpringWorks

Cerevel Therapeutics LLC (Boston, Mass.) hired Orly Mishan as CBO, a newly created role. She was principal and a founding member of Bain Capital Life Sciences, which launched the Pfizer Inc. (NYSE:PFE) spinout with $350...
BioCentury | Jun 12, 2019
Finance

How Bain plans to deploy $1B new fund

Bain Capital Life Sciences’ larger second fund could see the firm increasing its emphasis on investing in big biopharma spinouts after its debut fund featured investments in a pair of megarounds by Pfizer spin-offs. Bain...
BC Week In Review | Apr 12, 2019
Financial News

Bain files for new life sciences fund

Bain Capital is raising capital for its second life sciences fund, according to an SEC filing. The firm did not disclose in the filing how much it plans to raise for Bain Capital Life Sciences...
BC Week In Review | Dec 21, 2018
Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Dec. 19 that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon...
BC Extra | Dec 19, 2018
Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Wednesday that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon is...
Items per page:
1 - 10 of 31
BC Extra | Feb 1, 2020
Financial News

Arcutis gains in this year’s third biotherapeutic IPO on NASDAQ

The aftermarket performance of two IPOs in January’s final week suggests investors’ appetite for new biotech listings remains robust. In NASDAQ’s third biotherapeutic IPO of the year, dermatology company Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) raised $159.4...
BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BC Extra | Oct 22, 2019
Financial News

Crossover investors help Arcutis raise $95M to advance PDE-4 inhibitor for psoriasis

Arcutis raised $94.5 million in a series C financing to advance lead product ARQ-151, a topical formulation of the PDE-4 inhibitor roflumilast, through Phase III trials for mild-to-moderate psoriasis. Arcutis Biotherapeutics Inc. co-founder Chairman Bhaskar...
BC Extra | Sep 10, 2019
Financial News

Pharvaris raises $66M series B for clinical development of oral HAE therapy

Pharvaris will use its new $66 million series B round to fund early clinical development of its lead compound, an oral small molecule that could give HAE patients an easier-to-use option than existing injectable therapies...
BC Extra | Sep 9, 2019
Company News

Management tracks: Coles to lead Cerevel; plus Genfit, Jubilant, Paratek, Mogrify, Dementia Discovery Fund and Ayala

Cerevel Therapeutics LLC (Boston, Mass.) hired Tony Coles as CEO. Coles is Cerevel’s executive chairman as well as the co-founder and executive chairman of neurodegeneration company Yumanity Therapeutics LLC (Cambridge, Mass.), where he was until...
BC Extra | Aug 15, 2019
Company News

Management tracks: New executives at Pfizer spinouts Cerevel and SpringWorks

Cerevel Therapeutics LLC (Boston, Mass.) hired Orly Mishan as CBO, a newly created role. She was principal and a founding member of Bain Capital Life Sciences, which launched the Pfizer Inc. (NYSE:PFE) spinout with $350...
BioCentury | Jun 12, 2019
Finance

How Bain plans to deploy $1B new fund

Bain Capital Life Sciences’ larger second fund could see the firm increasing its emphasis on investing in big biopharma spinouts after its debut fund featured investments in a pair of megarounds by Pfizer spin-offs. Bain...
BC Week In Review | Apr 12, 2019
Financial News

Bain files for new life sciences fund

Bain Capital is raising capital for its second life sciences fund, according to an SEC filing. The firm did not disclose in the filing how much it plans to raise for Bain Capital Life Sciences...
BC Week In Review | Dec 21, 2018
Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Dec. 19 that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon...
BC Extra | Dec 19, 2018
Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Wednesday that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon is...
Items per page:
1 - 10 of 31